These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 21791914

  • 1. Fluorofenidone attenuates tubulointerstitial fibrosis by inhibiting TGF-β(1)-induced fibroblast activation.
    Yuan Q, Wang R, Peng Y, Fu X, Wang W, Wang L, Zhang F, Peng Z, Ning W, Hu G, Wang Z, Tao L.
    Am J Nephrol; 2011; 34(2):181-94. PubMed ID: 21791914
    [Abstract] [Full Text] [Related]

  • 2. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.
    Wang LH, Liu JS, Ning WB, Yuan QJ, Zhang FF, Peng ZZ, Lu MM, Luo RN, Fu X, Hu GY, Wang ZH, Tao LJ.
    Pharmacology; 2011; 88(1-2):88-99. PubMed ID: 21847000
    [Abstract] [Full Text] [Related]

  • 3. Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis.
    Qin J, Xie YY, Huang L, Yuan QJ, Mei WJ, Yuan XN, Hu GY, Cheng GJ, Tao LJ, Peng ZZ.
    Nephrology (Carlton); 2013 Oct; 18(10):690-9. PubMed ID: 23841831
    [Abstract] [Full Text] [Related]

  • 4. Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro.
    Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH, Zhang XM, Peng W, Cai H.
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1310-24. PubMed ID: 24879422
    [Abstract] [Full Text] [Related]

  • 5. Fluorofenidone inhibits transforming growth factor-beta1-induced cardiac myofibroblast differentiation.
    Chen LX, Yang K, Sun M, Chen Q, Wang ZH, Hu GY, Tao LJ.
    Pharmazie; 2012 May; 67(5):452-6. PubMed ID: 22764581
    [Abstract] [Full Text] [Related]

  • 6. Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and activation of hepatic stellate cells.
    Peng Y, Yang H, Wang N, Ouyang Y, Yi Y, Liao L, Shen H, Hu G, Wang Z, Tao L.
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(3):G253-63. PubMed ID: 24337009
    [Abstract] [Full Text] [Related]

  • 7. Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells.
    Yuan Q, Wang L, Zhang F, Wang R, Fu X, Peng Z, Ning W, Hu G, Wang Z, Tao L.
    Pharmazie; 2011 Dec; 66(12):961-7. PubMed ID: 22312703
    [Abstract] [Full Text] [Related]

  • 8. Fluorofenidone attenuates oxidative stress and renal fibrosis in obstructive nephropathy via blocking NOX2 (gp91phox) expression and inhibiting ERK/MAPK signaling pathway.
    Qin J, Mei WJ, Xie YY, Huang L, Yuan QJ, Hu GY, Tao LJ, Peng ZZ.
    Kidney Blood Press Res; 2015 Dec; 40(1):89-99. PubMed ID: 26029782
    [Abstract] [Full Text] [Related]

  • 9. Safflower extract: a novel renal fibrosis antagonist that functions by suppressing autocrine TGF-beta.
    Yang YL, Chang SY, Teng HC, Liu YS, Lee TC, Chuang LY, Guh JY, Chang FR, Liao TN, Huang JS, Yeh JH, Chang WT, Hung MY, Wang CJ, Chiang TA, Hung CY, Hung TJ.
    J Cell Biochem; 2008 Jun 01; 104(3):908-19. PubMed ID: 18189272
    [Abstract] [Full Text] [Related]

  • 10. You-gui Pill ameliorates renal tubulointerstitial fibrosis via inhibition of TGF-β/Smad signaling pathway.
    Wang L, Cao AL, Chi YF, Ju ZC, Yin PH, Zhang XM, Peng W.
    J Ethnopharmacol; 2015 Jul 01; 169():229-38. PubMed ID: 25922264
    [Abstract] [Full Text] [Related]

  • 11. Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril.
    Huang YR, Wei QX, Wan YG, Sun W, Mao ZM, Chen HL, Meng XJ, Shi XM, Tu Y, Zhu Q.
    J Ethnopharmacol; 2014 Sep 29; 155(3):1541-52. PubMed ID: 25087615
    [Abstract] [Full Text] [Related]

  • 12. [Effect of fluorofenidone on renal interstitial fibrosis in rats with unilateral ureteral obstruction].
    Tan W, Wang W, Zheng X, Chen J, Yuan X, Zhang F, Wang S, Tao L.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 May 28; 43(5):511-519. PubMed ID: 29886467
    [Abstract] [Full Text] [Related]

  • 13. LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction.
    Xie XS, Li FY, Liu HC, Deng Y, Li Z, Fan JM.
    Arch Pharm Res; 2010 Feb 28; 33(2):275-84. PubMed ID: 20195829
    [Abstract] [Full Text] [Related]

  • 14. [Prohibitin suppresses renal interstitial fibroblasts proliferation and phenotypic change induced by transforming growth factor-beta1].
    Guo W, Xu H, Huang WY, Chen J, Yang Y, Fu R, Liu HM, Zha XL, Zhang ZG.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 26; 87(24):1660-5. PubMed ID: 17825142
    [Abstract] [Full Text] [Related]

  • 15. Fluorofenidone attenuates TGF-β1-induced lung fibroblast activation via restoring the expression of caveolin-1.
    Liu J, Song C, Xiao Q, Hu G, Tao L, Meng J.
    Shock; 2015 Feb 26; 43(2):201-7. PubMed ID: 25394239
    [Abstract] [Full Text] [Related]

  • 16. Pirfenidone Attenuates Renal Tubulointerstitial Fibrosis through Inhibiting miR-21.
    Bi L, Huang Y, Li J, Yang X, Hou G, Zhai P, Zhang Q, Alhaji AA, Yang Y, Liu B.
    Nephron; 2022 Feb 26; 146(1):110-120. PubMed ID: 34724669
    [Abstract] [Full Text] [Related]

  • 17. Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition.
    Wang QL, Yuan JL, Tao YY, Zhang Y, Liu P, Liu CH.
    J Ethnopharmacol; 2010 Feb 17; 127(3):631-40. PubMed ID: 20015471
    [Abstract] [Full Text] [Related]

  • 18. The antifibrotic effect of a serine protease inhibitor in the kidney.
    Morinaga J, Kakizoe Y, Miyoshi T, Onoue T, Ueda M, Mizumoto T, Yamazoe R, Uchimura K, Hayata M, Shiraishi N, Adachi M, Sakai Y, Tomita K, Kitamura K.
    Am J Physiol Renal Physiol; 2013 Jul 15; 305(2):F173-81. PubMed ID: 23698112
    [Abstract] [Full Text] [Related]

  • 19. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro.
    Meng XM, Huang XR, Xiao J, Chen HY, Zhong X, Chung AC, Lan HY.
    J Pathol; 2012 Jun 15; 227(2):175-88. PubMed ID: 22190171
    [Abstract] [Full Text] [Related]

  • 20. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
    Li Z, Liu X, Wang B, Nie Y, Wen J, Wang Q, Gu C.
    Nephrology (Carlton); 2017 Aug 15; 22(8):589-597. PubMed ID: 27245114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.